Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells by Ross, David M., Pagani, Ilaria S., Shanmuganathan, Naranie, Kok, Chung H., Seymour, John F., Mills, Anthony K., Filshie, Robin J., Arthur, Christopher K., Dang, Phuong, Saunders, Verity A., Braley, Jodi, Yong, Agnes S., Yeung, David T., White, Deborah L., Grigg, Andrew P., Schwarer, Anthony P., Branford, Susan, Hughes, Timothy P.

Get full text

Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia by McQuilten, Zoe K., Busija, Ljoudmila, Seymour, John F., Stanworth, Simon, Wood, Erica M., Kenealy, Melita, Weinkove, Robert

Get full text

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy by Hughes, Timothy P., Branford, Susan, White, Deborah L., Reynolds, John, Koelmeyer, Rachel, Seymour, John F., Taylor, Kerry, Arthur, Chris, Schwarer, Anthony, Morton, James, Cooney, Julian, Leahy, Michael F., Rowlings, Philip, Catalano, John, Hertzberg, Mark, Filshie, Robin, Mills, Anthony K., Fay, Keith, Durrant, Simon, Januszewicz, Henry, Joske, David, Underhill, Craig, Dunkley, Scott, Lynch, Kevin, Grigg, Andrew

Get full text

A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma by Hapgood, Greg, Stone, Janey M., Zannino, Diana, George, Anup, Marlton, Paula, Prince, Henry Miles, Hui, Chi-Hung, Prosser, Ian, Lewis, Ian D., Bradstock, Kenneth, Seymour, John F.

Get full text

Managing hypogammaglobulinaemia secondary to haematological malignancies in Australia and New Zealand: a clinician survey by Wong, Jonathan, Wood, Erica M., Crispin, Philip, Weinkove, Robert, McQuilten, Zoe K.

Get full text

Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies by Tiong, Ing S., Reynolds, John, Bradstock, Kenneth F., Seymour, John F., Wei, Andrew H.

Get full text

Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin... by Grigg, Andrew P., Stone, Janey, Milner, Alvin D., Schwarer, Anthony P., Wolf, Max, Prince, H. Miles, Seymour, John, Gill, Devinder, Ellis, David, Bashford, John

Get full text

Prognostic features for response and survival in elderly patients with de novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine by Grigg, AP, Reynolds, J, McQuillan, A, Juneja, SK, Iulio, J Di, Hui, C, Smith, C, Kimber, R, Bradstock, KF, on behalf of the Australasian Leukaemia and Lymphoma Group

Get full text

A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY1... by Mead, Graham M., Barrans, Sharon L., Qian, Wendi, Walewski, Jan, Radford, John A., Wolf, Max, Clawson, Simon M., Stenning, Sally P., Yule, Claire L., Jack, Andrew S.

Get full text

O01 Twenty-five years of clinical trials for adult Acute Myeloid Leukaemia (AML) in Australia by Lowenthal, R.M, Seymour, J.F

Get full text

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study by Campbell, Peter J, Scott, Linda M, Buck, Georgina, Wheatley, Keith, East, Clare L, Marsden, Joanne T, Duffy, Audrey, Boyd, Elaine M, Bench, Anthony J, Scott, Mike A, Vassiliou, George S, Milligan, Donald W, Smith, Steve R, Erber, Wendy N, Bareford, David, Wilkins, Bridget S, Reilly, John T, Harrison, Claire N, Green, Anthony R

Get full text